Biotech startups that raised Series A in North America
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Zafrens | San Diego | Series A | $6.0M | 2026-11-03 |
| Specific Biologics | Toronto | Series A | $35.0M | 2026-11-02 |
| Probably Genetic | San Francisco | Series A | $12.0M | 2026-10-15 |
| Biotia | Long Island City | Series A | $9.0M | 2026-10-01 |
| ai3Bio | Pittsburgh | Series A | $48.0M | 2026-09-29 |
| Arkea Bio | Charlestown | Series A | $15.0M | 2026-09-29 |
| Ramona | Durham | Series A | $25.0M | 2026-09-22 |
| ImpriMed | Palo Alto | Series A | $10.0M | 2026-09-18 |
8 rows of the CSV in 5 of its 18 columns.
- The 1,108 biotech startups in North America whose last round is Series A have raised $40.7B in total.
- 133 of them closed their most recent round in the last 12 months, $5.5B combined.
- The largest of those rounds is Solstice Oncology's $225.0M Series A, dated September 2026.
- The most recent is Signet Therapeutics' $11.5M Series A on 4 November 2026.
- National Science Foundation is an investor in 15 of them, more than any other fund.
- Health care is the most common other sector, with 931 companies (84%).
- 27% were founded in 2020 or later; the median founding year is 2016.
- The most common team size is 11 to 50 employees (56% of companies with a recorded size).
- 2 are unicorns, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 1,108| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Zafrens | Zafrens provides a throughput platform that links molecular profiles to cell phenotypes for drug discovery. | Biotech | San Diego, United States | Series A | $6.0M | 2026-11-03 | $35.0M | Liquid 2 Ventures, Global Brain Corporation, BlueYard Capital +2 | 11 to 50 | 2022 |
| Specific Biologics | Specific Biologics develops gene editing technologies to treat diseases at the genetic level inside the body. | Biotech | Toronto, Canada | Series A | $35.0M | 2026-11-02 | $36.3M | Creative Destruction Lab, Lumira Ventures, adMare Bio Innovations | 1 to 10 | 2017 |
| Probably Genetic | Probably Genetic develops treatments aimed at improving the lives of patients with severe, complex diseases. | Artificial intelligence | San Francisco, United States | Series A | $12.0M | 2026-10-15 | $22.9M | Y Combinator, Khosla Ventures, TenOneTen Ventures +2 | 11 to 50 | 2018 |
| Biotia | Biotia is a health tech startup that offers AI solutions to diagnose and control infectious diseases. | Artificial intelligence | Long Island City, United States | Series A | $9.0M | 2026-10-01 | $19.7M | Everywhere Ventures, Sand Hill Angels, Tau Ventures +2 | 11 to 50 | 2016 |
| ai3Bio | ai3Bio develops cancer treatments for patients. | Biotech | Pittsburgh, United States | Series A | $48.0M | 2026-09-29 | $103.0M | UPMC Enterprises | 11 to 50 | 2019 |
| Arkea Bio | Arkea Bio develops technology that reduces greenhouse gas emissions from agriculture. | Biotech | Charlestown, United States | Series A | $15.0M | 2026-09-29 | $60.5M | Breakthrough Energy Ventures, Overview, Rabo Ventures | 11 to 50 | 2021 |
| Ramona | Ramona develops high-throughput microscopy tools for biology labs. | Artificial intelligence | Durham, United States | Series A | $25.0M | 2026-09-22 | $59.7M | National Science Foundation, National Institutes of Health, E14 Fund +1 | 11 to 50 | 2017 |
| ImpriMed | ImpriMed provides AI-driven precision medicine services to oncologists and pharmaceutical companies. | Artificial intelligence | Palo Alto, United States | Series A | $10.0M | 2026-09-18 | $44.7M | Plug and Play, Pear VC, Draper Associates +1 | 51 to 100 | 2017 |
| Altis Labs | Altis Labs uses AI endpoints to speed clinical trials so new treatments reach patients sooner. | Artificial intelligence | Toronto, Canada | Series A | $25.0M | 2026-09-17 | $31.0M | Creative Destruction Lab, Debiopharm Innovation Fund, Benchstrength | 11 to 50 | 2019 |
| Evia Bio | Evia Bio develops non-DMSO cryopreservation solutions for life sciences. | Biotech | Minneapolis, United States | Series A | $5.5M | 2026-09-16 | $5.7M | Newchip Accelerator, Pleasant Bay Capital Partners, Walleye Tank | 1 to 10 | 2019 |
| Mithrl | Mithrl is a software development company that builds custom NGS data workflows on demand. | Artificial intelligence | San Francisco, United States | Series A | $20.0M | 2026-09-15 | $24.0M | Bonfire Ventures | 51 to 100 | 2023 |
| TwoStep Therapeutics | TwoStep Therapeutics develops tumor-targeting therapeutics for solid tumors. | Biotech | Palo Alto, United States | Series A | $62.5M | 2026-09-09 | $90.1M | NFX, 2048 Ventures, Alexandria Venture Investments +1 | 11 to 50 | 2023 |
| Remedium Bio | Remedium Bio develops gene therapy treatments for various diseases. | Biotech | Needham, United States | Series A | $10.0M | 2026-08-10 | $13.8M | National Science Foundation, MicroVentures, Longevitytech.fund +1 | 11 to 50 | 2020 |
| Integrated Biosciences | Integrated Bio develops multimodal biological datasets and AI for drug discovery against age-related diseases. | Artificial intelligence | Redwood City, United States | Series A | $68.4M | 2026-08-05 | $85.6M | Root Ventures, Reinforced Ventures, Mission BioCapital +2 | 11 to 50 | 2022 |
| Dash Bio | Dash Bio develops automated laboratory workflows and software to support drug development through bioanalysis services. | Artificial intelligence | Boston, United States | Series A | $30.0M | 2026-08-03 | $47.5M | Freestyle Capital, Swift Ventures, LifeX Ventures +1 | 11 to 50 | 2024 |
| Transcripta Bio | Transcripta Bio develops drugs at an accelerated pace with reduced risk. | Biotech | Palo Alto, United States | Series A | $24.0M | 2026-07-22 | $34.4M | BlueYard Capital, Jazz Venture Partners | 11 to 50 | 2020 |
| Xellar Biosystems | Xellar Biosystems analyzes drug testing and treatment data using artificial intelligence. | Artificial intelligence | Newton, United States | Series A | $29.5M | 2026-06-30 | $93.2M | Legend Capital, Tiantu Capital, Zhengxuan Investment +1 | 11 to 50 | 2022 |
| Waypoint Bio | Waypoint Bio applies spatial biology to improve cell therapy development. | Artificial intelligence | New York, United States | Series A | $20.0M | 2026-05-27 | $34.5M | Village Global, Fifty Years, Hummingbird Ventures +2 | 11 to 50 | 2021 |
| Kanvas Biosciences | Kanvas Biosciences maps molecular interactions to support therapeutic discovery and human health. | Biotech | Monmouth Junction, United States | Series A | $48.0M | 2026-05-05 | $76.4M | DCVC, Pangaea Ventures, Germin8 Ventures +2 | 11 to 50 | 2020 |
| Latus Bio | Latus Bio develops gene therapies for central nervous system disorders using screened AAV capsids. | Biotech | Philadelphia, United States | Series A | $43.0M | 2026-05-04 | $97.0M | Gaingels, 8VC, Ben Franklin Technology Partners +1 | 11 to 50 | 2022 |
| Future Fertility | Future Fertility provides artificial intelligence tools for reproductive medicine. | Artificial intelligence | Toronto, Canada | Series A | $4.1M | 2026-04-23 | $4.1M | M Ventures, Whitecap Venture Partners | 11 to 50 | 2018 |
| Gilgamesh Pharmaceuticals | Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company developing psychedelic drugs to treat mental illness. | Biotech | New York, United States | Series A | $60.0M | 2026-03-24 | $142.6M | Y Combinator, Alumni Ventures, Gaingels +2 | 11 to 50 | 2019 |
| Condor Software | Condor Software is a financial intelligence platform that connects clinical, operational, and financial data in real time. | Biotech | San Diego, United States | Series A | $24.0M | 2026-03-18 | $29.5M | Plug and Play, MassChallenge, Pareto Holdings +1 | 11 to 50 | 2020 |
| Stata DX | Stata DX develops eRapid disease management technology for implementing custom biomarker panels in clinical studies. | Biotech | Cambridge, United States | Series A | $400K | 2026-02-27 | $3.6M | MassVentures | 1 to 10 | 2022 |
| Third Arc Bio | Third Arc Bio develops multifunctional antibodies for inflammatory and immunology diseases. | Biotech | Boston, United States | Series A | $52.0M | 2026-02-04 | $217.0M | T. Rowe Price, Cormorant Asset Management, Foresite Capital +1 | 11 to 50 | 2022 |
| Prenosis | Prenosis develops data-driven diagnostic tools and precision medicine solutions for acute care conditions. | Artificial intelligence | Chicago, United States | Series A | $20.0M | 2026-01-29 | $31.5M | National Science Foundation, PACE Healthcare Capital, Defense Threat Reduction Agency (DTRA) | 11 to 50 | 2014 |
| Think Bioscience | Think Bioscience designs and assembles medicines using living systems through synthetic biology. | Biotech | Boulder, United States | Series A | $55.0M | 2026-01-20 | $78.3M | National Science Foundation, Innovation Endeavors, Wireframe Ventures +2 | 11 to 50 | 2019 |
| Prudentia Sciences | Prudentia Sciences provides AI-powered asset diligence and valuation to reduce risk in drug development investment. | Artificial intelligence | Cambridge, United States | Series A | $20.0M | 2026-01-07 | $27.0M | Google Ventures, Iaso Ventures, Virtue | 1 to 10 | 2023 |
| Neurable | Neurable develops AI tools for translating brain signals and brain-computer interface technology. | Artificial intelligence | Boston, United States | Series A | $35.0M | 2025-12-19 | $57.3M | National Science Foundation, Global Brain Corporation, Metaplanet +1 | 11 to 50 | 2015 |
| Medra AI | Medra AI builds an autonomous scientific experimentation platform that combines robotics with artificial intelligence. | Artificial intelligence | San Francisco, United States | Series A | $52.0M | 2025-12-11 | $63.0M | PharmStars | 11 to 50 | 2021 |
Table 1. Biotech startups that raised Series A in North America: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 1,108.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Integrated Biosciences | Integrated Bio develops multimodal biological datasets and AI for drug discovery against age-related diseases. | Artificial intelligence | Redwood City, United States | Series A | $68.4M | 2026-08-05 | $85.6M | Root Ventures, Reinforced Ventures, Mission BioCapital +2 | 11 to 50 | 2022 |
| 2 | TwoStep Therapeutics | TwoStep Therapeutics develops tumor-targeting therapeutics for solid tumors. | Biotech | Palo Alto, United States | Series A | $62.5M | 2026-09-09 | $90.1M | NFX, 2048 Ventures, Alexandria Venture Investments +1 | 11 to 50 | 2023 |
| 3 | Gilgamesh Pharmaceuticals | Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company developing psychedelic drugs to treat mental illness. | Biotech | New York, United States | Series A | $60.0M | 2026-03-24 | $142.6M | Y Combinator, Alumni Ventures, Gaingels +2 | 11 to 50 | 2019 |
| 4 | Think Bioscience | Think Bioscience designs and assembles medicines using living systems through synthetic biology. | Biotech | Boulder, United States | Series A | $55.0M | 2026-01-20 | $78.3M | National Science Foundation, Innovation Endeavors, Wireframe Ventures +2 | 11 to 50 | 2019 |
| 5 | Third Arc Bio | Third Arc Bio develops multifunctional antibodies for inflammatory and immunology diseases. | Biotech | Boston, United States | Series A | $52.0M | 2026-02-04 | $217.0M | T. Rowe Price, Cormorant Asset Management, Foresite Capital +1 | 11 to 50 | 2022 |
| 6 | Medra AI | Medra AI builds an autonomous scientific experimentation platform that combines robotics with artificial intelligence. | Artificial intelligence | San Francisco, United States | Series A | $52.0M | 2025-12-11 | $63.0M | PharmStars | 11 to 50 | 2021 |
| 7 | ai3Bio | ai3Bio develops cancer treatments for patients. | Biotech | Pittsburgh, United States | Series A | $48.0M | 2026-09-29 | $103.0M | UPMC Enterprises | 11 to 50 | 2019 |
| 8 | Kanvas Biosciences | Kanvas Biosciences maps molecular interactions to support therapeutic discovery and human health. | Biotech | Monmouth Junction, United States | Series A | $48.0M | 2026-05-05 | $76.4M | DCVC, Pangaea Ventures, Germin8 Ventures +2 | 11 to 50 | 2020 |
| 9 | Latus Bio | Latus Bio develops gene therapies for central nervous system disorders using screened AAV capsids. | Biotech | Philadelphia, United States | Series A | $43.0M | 2026-05-04 | $97.0M | Gaingels, 8VC, Ben Franklin Technology Partners +1 | 11 to 50 | 2022 |
| 10 | AI Proteins | AI Proteins designs and engineers miniprotein therapeutics using artificial intelligence. | Artificial intelligence | Boston, United States | Series A | $42.5M | 2025-11-19 | $80.4M | Intel Ignite, Lightchain Capital, Cobro Ventures | 11 to 50 | 2021 |
Table 2. Biotech startups that raised Series A in North America: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | National Science Foundation | Entrepreneurship program | Alexandria, United States | 15 | 1% | 5 | Ramona, Remedium Bio, Prenosis |
| 2 | Y Combinator | Startup accelerator | Mountain View, United States | 11 | 1% | 3 | Probably Genetic, Gilgamesh Pharmaceuticals, Arpeggio Bio |
| 3 | Alexandria Venture Investments | Venture capital firm | Pasadena, United States | 9 | 1% | 1 | TwoStep Therapeutics |
| 4 | National Institutes of Health | Entrepreneurship program | Bethesda, United States | 8 | 1% | 1 | Ramona |
| 5 | Alumni Ventures | Angel group | Manchester, United States | 8 | 1% | 1 | Gilgamesh Pharmaceuticals |
| 6 | Andreessen Horowitz | Venture capital firm | Menlo Park, United States | 8 | 1% | ||
| 7 | ARCH Venture Partners | Venture capital firm | Chicago, United States | 8 | 1% | ||
| 8 | MassChallenge | Startup accelerator | Boston, United States | 7 | 1% | 1 | Condor Software |
| 9 | Plug and Play | Startup accelerator | Sunnyvale, United States | 6 | 1% | 2 | ImpriMed, Condor Software |
| 10 | F-Prime | Venture capital firm | Cambridge, United States | 6 | 1% | ||
| 11 | Liquid 2 Ventures | Venture capital firm | San Francisco, United States | 4 | 0% | 1 | Zafrens |
| 12 | Creative Destruction Lab | Entrepreneurship program | Toronto, Canada | 4 | 0% | 2 | Specific Biologics, Altis Labs |
| 13 | Khosla Ventures | Venture capital firm | Menlo Park, United States | 4 | 0% | 2 | Probably Genetic, Arpeggio Bio |
| 14 | Newchip Accelerator | Startup accelerator | Austin, United States | 4 | 0% | 1 | Evia Bio |
| 15 | DCVC | Venture capital firm | Palo Alto, United States | 4 | 0% | 1 | Kanvas Biosciences |
Table 3. Biotech startups that raised Series A in North America: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 931 | 84% | $36.4B |
| Software | 162 | 15% | $4.8B |
| Artificial intelligence | 99 | 9% | $3.8B |
| Hardware | 41 | 4% | $622.9M |
| Cybersecurity | 12 | 1% | $106.3M |
| Energy | 12 | 1% | $445.4M |
| Commerce | 6 | 1% | $103.0M |
| Fintech | 6 | 1% | $50.0M |
| Education | 5 | 0% | $43.4M |
Table 4. Biotech startups that raised Series A in North America by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series A | 1,108 | 100% | $15.0M |
Table 5. Biotech startups that raised Series A in North America by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| United States | 1,063 | 96% |
| Canada | 40 | 4% |
| Mexico | 5 | 0% |
Table 6. Biotech startups that raised Series A in North America by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 7. Biotech startups that raised Series A in North America by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 3 | 2% | $52.5M |
| October 2026 | 10 | 8% | $501.3M |
| September 2026 | 17 | 13% | $768.7M |
| August 2026 | 11 | 8% | $298.2M |
| July 2026 | 6 | 5% | $81.6M |
| June 2026 | 14 | 11% | $423.2M |
| May 2026 | 11 | 8% | $451.9M |
| April 2026 | 6 | 5% | $319.6M |
| March 2026 | 11 | 8% | $290.4M |
| February 2026 | 7 | 5% | $285.1M |
| January 2026 | 16 | 12% | $1.0B |
| December 2025 | 15 | 11% | $634.2M |
| November 2025 | 6 | 5% | $331.6M |
Table 8. Biotech startups that raised Series A in North America: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 112 | 10% | $4.5B |
| 2025 | 123 | 11% | $5.2B |
| 2024 | 77 | 7% | $4.0B |
| 2023 | 91 | 8% | $3.0B |
| 2022 | 111 | 10% | $3.3B |
| 2021 | 120 | 11% | $6.0B |
Table 9. Biotech startups that raised Series A in North America by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 82 | 7% |
| 2020 to 2022 | 214 | 19% |
| 2015 to 2019 | 371 | 34% |
| 2010 to 2014 | 221 | 20% |
| Before 2010 | 210 | 19% |
Table 10. Biotech startups that raised Series A in North America by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 371 | 34% |
| 11 to 50 | 608 | 56% |
| 51 to 100 | 68 | 6% |
| 101 to 250 | 24 | 2% |
| 251 to 500 | 5 | 0% |
| 501 to 1,000 | 6 | 1% |
| 1,001 to 5,000 | 2 | 0% |
| 5,001 to 10,000 | 2 | 0% |
| 10,001 or more | 3 | 0% |
Table 11. Biotech startups that raised Series A in North America by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series A and its headquarters is in North America. On 16 November 2026 that is 1,108 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 1,108 rows: 124 have no round amount, 0 no city and 168 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in North America whose last round is Series A are on the list?
- 1,108, in the file dated 16 November 2026. 133 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 1,108 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $349.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.